A clinical and molecular analysis of Candidozyma auris strains from Romania, 2022-2023

Marius Surleac1,2, Adriana Mihaela Stanciu2,3, Dragoș Florea2,3

  • 1Research Institute of the University of Bucharest, University of Bucharest, Bucharest, Romania.

PubMed

Insights

Candidozyma auris causes severe infections and is resistant to antifungals. This study of 102 patients reveals its spread and resistance patterns, highlighting the need for surveillance and control.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Genomics

Background:

  • Candidozyma auris (formerly Candida auris) poses a significant threat due to antifungal resistance and transmissibility.
  • Healthcare facilities face challenges managing C. auris infections.

Purpose of the Study:

  • To analyze the clinical, epidemiological, and molecular characteristics of C. auris infections.
  • To understand the genomic diversity and antifungal resistance of C. auris isolates.
  • To inform surveillance and infection control strategies.

Main Methods:

  • Retrospective study of 102 patients diagnosed between 2022-2023.
  • Identification using MALDI-TOF, antifungal susceptibility testing (Micronaut), and whole-genome sequencing (Illumina).
  • Bioinformatic analysis including phylogenetic, resistance gene, and variant analyses.

Main Results:

  • Most patients (80/102) were in intensive care units.
  • All 31 tested isolates were resistant to fluconazole; 5 were resistant to amphotericin B.
  • All isolates were susceptible to echinocandins; crude mortality was 68.18% for infected patients.
  • Sequenced isolates belonged to clade I and showed multiple resistance markers.

Conclusions:

  • C. auris outbreaks require active surveillance and robust infection control.
  • Clade I isolates exhibit high antifungal resistance, necessitating tailored treatment strategies.
  • Genomic insights are crucial for managing this emerging global health threat.